A recognized authority on prostate cancer, urologist John H. Lynch, MD, has been affiliated with MedStar Georgetown University Hospital and the Georgetown University School of Medicine since 1979. During his career, he has held numerous leadership positions at both institutions, including a 2002 appointment as professor and chair of the Department of Urology which he still holds. Dr. Lynch is currently the president of the American Urological Association.
Dr. Lynch is an active researcher and has served as principal investigator or co-investigator for numerous industry and federal grants over the years, including multi-year awards from NIH, DOD and CDC. His work has been published widely in national and international professional journals.
Dr. Lynch has won many awards for his teaching abilities, and regularly appears in Washingtonian magazine's "Top Doctors" edition, among other recognitions.
Philosophy of Care
As a prostate cancer survivor myself, I know on a very personal level how difficult and frightening this diagnosis can be. But while prostate cancer is the most common cancer in men, it is also the most treatable. I use my experience and perspective to approach and treat every patient like a family member and help them during this often emotional time.
Rana Z, Cyr RA, Chen LN, Kim BS, Moures RA, Yung TM, Lei S, Collins BT, Suy S, Dritschilo A, Lynch JH, Collins SP. Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancer. Front Oncol. 2014 Oct 21;4:290.
Joh DY, Chen LN, Porter G, Bhagat A, Sood S, Kim JS, Moures R, Yung T, Lei S, Collins BT, Ju AW, Suy S, Carroll J, Lynch JH, Dritschilo A, Collins SP. Proctitis following stereotactic body radiation therapy for prostate cancer. Radiat Oncol. 2014 Dec 12;9:277.
Woo JA, Chen LN, Wang H, Cyr RA, Bhattasali O, Kim JS, Moures R, Yung TM, Lei S, Collins BT, Suy S, Dritschilo A, Lynch JH, Collins SP. Stereotactic body Radiation Therapy for Prostate cancer: What is the appropriate patient-reported outcome for Clinical Trial Design? Front Oncol 2015 Mar 31;5:77.
Gurka MK, Chen LN, Bhagat A, Coures R, Kim JS, yung T, Lei S, Collins BT, Krishnan P, Suy S, Dritschilo A, Lynch JH, Collins SP. Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. Radiat Oncol. 2015 Feb 19;10:44.
Janowski EM, Kole TP, Chen LN, Kim JS, Yung TM, Collins BT, Suy S, Lynch JH, Dritschilo A, Collins SP. Dysuria following stereotactic body radiation therapy for prostate cancer. Paydar I, Kim BS, Cyr RA, Rashid H, Anjum A, Yung TM, Lei S, Collins BT, Suy S, Dritschilo A, Lynch JH, Collins SP. Urethrogram-directed stereotactic body radiation therapy for clinically localized prostate cancer in patients with contraindications to Magnetic Resonance Imaging. Front Oncol. 2015 Sep 1;5:194.
Tsai HT, Penson D, Luta G, Lynch JH, Zhou Y, Potosky AL. Adoption of intermittent androgen deprivation therapy for advanced prostate cancer: A population based study in American Urology Practice. Urol Pract. 2015 Jul; 2(4): 190-198.
Mercado C, Kress MA, Cyr RA, Chen LN, Yung TM, Bullock EG, Lei S, Collins BT, Satinsky AN, Harter KW, Suy S, Dritschilo A, Lynch JH, Collins SP. Intensity-modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: The Georgetown University Experience. Front Oncol. 2016 May 6;6:114.